Last reviewed · How we verify
Fibrinogen
At a glance
| Generic name | Fibrinogen |
|---|---|
| Also known as | Riastap®, CSL Behring, Active drug, Riastap, Haemocomplettan, Fibrinogen Concentrate (Human) Injection [Fibryga] |
| Sponsor | Rigshospitalet, Denmark |
| Drug class | Human Blood Coagulation Factor [EPC] |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Skin graft failure
- Hematoma/seroma
- Hematoma
- Pruritus
Serious adverse events
- Air embolism
Key clinical trials
- Goal-Directed Hemostatic Resuscitation Trial in ACLF Induced Coagulopathy (NA)
- Biological and Clinical Relevance of Quantra Viscoelastic Hemostatic Assay in Hemorrhagic Cardiac Surgery
- PS-002 for the Treatment of IgA Nephropathy in Adults (PHASE1, PHASE2)
- Autologous Whole Blood Management for Transfusion Reduction in Adult Cardiac Surgery Patients (NA)
- Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery (PHASE3)
- System-IGF-1 Pathway and Alzheimer's Disease
- Impact of the Reimbursement of Fibrinogen in Cardiac Surgery
- Comparison of Fibrinogen Concentrate and Cryoprecipitate in Pediatric Cardiac Surgery Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |